



SmartPA Criteria Proposal

Drug/Drug Class:	Corticosteroids, Topical PDL Edit		
First Implementation Date:	June 21, 2012		
Revised Date:	July 1, 2021		
Prepared For:	MO HealthNet		
Prepared By:	MO HealthNet/Conduent		
Criteria Status:	□Existing Criteria ⊠Revision of Existing Criteria □New Criteria		

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected:

Topical corticosteroids are used for a variety of inflammatory skin conditions, including atopic dermatitis, seborrheic dermatitis, eczema, and plaque psoriasis.

Pharmacotherapy choices for these conditions typically include emollients and topical corticosteroids. Emollients play an important role in the treatment of atopic dermatitis; however, topical steroids are the standard of care to which other treatments are compared. The selected potency should depend on the severity and location of disease. These agents control symptoms such as swelling, skin cracking, weeping, crusting, and scaling. This PDL class includes all potency classes and does not require additional criteria to gain access to or move from one group to another.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information

С	Preferred Agents	Non-Preferred Agents
: 	 Anusol-HC® Betamethasone Dip Lot Betamethasone Val Crm/Lot/Oint Clobetasol Emollient Crm Clobetasol Prop Crm/Gel/Oint/Soln Fluticasone Prop Crm/Oint Hydrocortisone Crm/Lot/Oint Rx Hydrocortisone Crm/Oint OTC Mometasone Procto-Med HC™ Proctosol-HC® Proctozone-HC® Triamcinolone Crm/Lot/Oint (excluding gen Trianex®) 	Ala-Scalp® Alclometasone Dip Amcinonide Apexicon E® Aqua Glycolic® HC Kit Beser™ Betamethasone Dip Aug Crm/Gel/Lot/Oint Betamethasone Dip Crm/Oint Betamethasone Val Foam Bryhali® Capex® Clobetasol Emollient Foam Clobetasol Prop Foam/Lot/Shampoo/Spray Clocortolone Clodan®

SmartPA PDL Proposal Form

- Cordran[®]
- Cutivate[®]
- Derma-Smoothe/FS®
- Dermatop[®]
- Desonate[®]
- Desonide
- Desowen[®]
- Desoximetasone
- Diflorasone Crm/Oint
- Diprolene[®]
- Elocon[®]
- Fluocinolone
- Fluocinonide
- Fluocinonide Emollient
- Flurandrenolide
- Fluticasone Prop Lot
- Halcinonide
- Halobetasol
- Halog[®]
- Hydrocortisone Absorbase Rx
- Hydrocortisone Butyrate
- Hydrocortisone Lot OTC
- Hydrocortisone Valerate
- Hydrocortisone/Aloe
- Impeklo[™]
- Impoyz[®]
- Kenalog®
- Lexette[®]
- Locoid[®]
- Locoid Lipocream[®]
- Luxiq[®]
- Micort-HC[®]
- Nolix[®]
- Nucort[™]
- Olux[®]
- Olux-E[®]
- Pandel[®]
- Prednicarbate
- Procto-Pak[™]
- Psorcon[®]
- Sernivo[®]
- Synalar[®]
- Temovate®
- Texacort[®]
- Topicort[®]
- Tovet[™]
- Triamcinolone 0.05% Oint (gen Trianex[®])
- Triamcinolone Acet Aerosol
- Trianex[®]
- Triderm[™]
- Tridesilon®
- Ultravate®

			Ultravate® X						
			Vanos®						
			Verdeso®						
Type of Criteria:	☐ Increased risk of ADE☐ Appropriate Indications		☑ Preferred Drug List☐ Clinical Edit						
Data Sources:	☐ Only Administra	tive Databases	□ Databases + Pres	criber-Supplied					
Setting & Population									
 Drug class for review: Corticosteroids, Topical Age range: All appropriate MO HealthNet participants 									
Approval Criteria									
 Failure to achieve desired therapeutic outcomes with trial on 4 or more preferred agents Documented trial period of preferred agents OR Documented ADE/ADR to preferred agents 									
Denial Criteria									
 Lack of adequate trial on required preferred agents Therapy will be denied if all approval criteria are not met 									
Required Documentation									
Laboratory Resul MedWatch Form		Progress Notes: Other:							
Disposition of Edit									
Denial: Exception Code "0160" (Preferred Drug List) Rule Type: PDL									
Default Approval Period									
1 year									

References

- 1. Evidence-Based Medicine and Fiscal Analysis: "Topical Corticosteroids Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2021.
- 2. Evidence-Based Medicine Analysis: "Topical Corticosteroids for Dermatological Disorders", UMKC-DIC; January 2021.
- 3. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2021.
- 4. USPDI, Micromedex; 2021.
- 5. Facts and Comparisons eAnswers (online); 2021 Clinical Drug Information, LLC.

SmartPA PDL Proposal Form